PCNSL

11 registered clinical trials studyying PCNSL — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PC NCT07350850	Tongji Hospital	Phase 2
Recruiting	A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervo NCT06554561	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1 / Phase 2
Unknown	Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT NCT05896007	Ruijin Hospital	Phase 2
Active Not Recruiting	Real World Data on Ibrutinib Use in PCNSL Rel/Ref NCT05782374	IRCCS San Raffaele	—
Unknown	Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma NCT05021770	Huiqiang Huang	Phase 1 / Phase 2
Unknown	Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma NCT04514393	Huiqiang Huang	Phase 2
Unknown	Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Cen NCT04481815	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Unknown	A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL NCT04438044	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 2
Completed	A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteris NCT06914700	Guangdong Provincial People's Hospital	—
Unknown	Bendamustine-based Combination Therapy for PCNSL NCT03392714	Chonnam National University Hospital	Phase 2
Unknown	Prognosis Factors in Patients With Primary Central Nervous System Lymphoma NCT05167630	Zhengzhou University	—